Impact BioMedical, Inc. (IBO)
0.453
-0.03
(-5.62%)
USD |
NYAM |
Aug 24, 16:00
0.4596
+0.01
(+1.46%)
After-Hours: 20:00
Impact BioMedical Enterprise Value : 52.08M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 52.08M |
| August 21, 2026 | 54.99M |
| August 20, 2026 | 51.68M |
| August 19, 2026 | 49.94M |
| August 18, 2026 | 53.91M |
| August 17, 2026 | 54.71M |
| August 14, 2026 | 52.76M |
| August 13, 2026 | 50.68M |
| August 12, 2026 | 51.43M |
| August 11, 2026 | 49.60M |
| August 10, 2026 | 50.19M |
| August 07, 2026 | 50.15M |
| August 06, 2026 | 51.84M |
| August 05, 2026 | 49.60M |
| August 04, 2026 | 50.68M |
| August 03, 2026 | 50.57M |
| July 31, 2026 | 49.60M |
| July 30, 2026 | 49.60M |
| July 29, 2026 | 49.22M |
| July 28, 2026 | 49.60M |
| July 27, 2026 | 49.81M |
| July 24, 2026 | 50.68M |
| July 23, 2026 | 49.63M |
| July 22, 2026 | 49.63M |
| July 21, 2026 | 50.79M |
| Date | Value |
|---|---|
| July 20, 2026 | 51.22M |
| July 17, 2026 | 52.40M |
| July 16, 2026 | 52.40M |
| July 15, 2026 | 52.83M |
| July 14, 2026 | 54.99M |
| July 13, 2026 | 53.16M |
| July 10, 2026 | 50.89M |
| July 09, 2026 | 52.03M |
| July 08, 2026 | 51.94M |
| July 07, 2026 | 51.94M |
| July 06, 2026 | 54.67M |
| July 02, 2026 | 54.13M |
| July 01, 2026 | 55.42M |
| June 30, 2026 | 52.83M |
| June 29, 2026 | 57.49M |
| June 26, 2026 | 54.01M |
| June 25, 2026 | 54.55M |
| June 24, 2026 | 56.89M |
| June 23, 2026 | 61.22M |
| June 22, 2026 | 60.60M |
| June 18, 2026 | 57.37M |
| June 17, 2026 | 65.44M |
| June 16, 2026 | 62.06M |
| June 15, 2026 | 62.74M |
| June 12, 2026 | 66.30M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Enveric Biosciences, Inc. | -2.747M |
| LENZ Therapeutics, Inc. | -75.23M |
| ANI Pharmaceuticals, Inc. | 1.938B |
| Corcept Therapeutics, Inc. | 13.00B |
| Veru, Inc. | 21.05M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.70M |
| Revenue (Quarterly) | 0.003M |
| Total Expenses (Quarterly) | 0.702M |
| EPS Diluted (Quarterly) | -0.0065 |
| Gross Profit Margin (Quarterly) | -9.40K% |
| Profit Margin (Quarterly) | -23.33K% |
| Earnings Yield | -21.68% |
| Normalized Earnings Yield | -23.93 |